UNITED THERAPEUTICS CORP (UTHR) Stock Fundamental Analysis

NASDAQ:UTHR • US91307C1027

507.91 USD
+4.01 (+0.8%)
Last: Mar 2, 2026, 01:48 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Overall UTHR gets a fundamental rating of 7 out of 10. We evaluated UTHR against 520 industry peers in the Biotechnology industry. UTHR gets an excellent profitability rating and is at the same time showing great financial health properties. UTHR has a decent growth rate and is not valued too expensively. These ratings could make UTHR a good candidate for quality investing.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year UTHR was profitable.
  • UTHR had a positive operating cash flow in the past year.
  • Each year in the past 5 years UTHR has been profitable.
  • In the past 5 years UTHR always reported a positive cash flow from operatings.
UTHR Yearly Net Income VS EBIT VS OCF VS FCFUTHR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 16.94%, UTHR belongs to the top of the industry, outperforming 95.77% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 18.81%, UTHR belongs to the top of the industry, outperforming 95.58% of the companies in the same industry.
  • UTHR has a Return On Invested Capital of 16.10%. This is amongst the best in the industry. UTHR outperforms 96.73% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for UTHR is in line with the industry average of 17.87%.
  • The last Return On Invested Capital (16.10%) for UTHR is above the 3 year average (15.88%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 16.94%
ROE 18.81%
ROIC 16.1%
ROA(3y)15.64%
ROA(5y)13.63%
ROE(3y)17.94%
ROE(5y)16.2%
ROIC(3y)15.88%
ROIC(5y)14.43%
UTHR Yearly ROA, ROE, ROICUTHR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • Looking at the Profit Margin, with a value of 41.94%, UTHR belongs to the top of the industry, outperforming 97.88% of the companies in the same industry.
  • UTHR's Profit Margin has improved in the last couple of years.
  • UTHR has a better Operating Margin (47.63%) than 99.62% of its industry peers.
  • UTHR's Operating Margin has improved in the last couple of years.
  • The Gross Margin of UTHR (87.92%) is better than 89.62% of its industry peers.
  • In the last couple of years the Gross Margin of UTHR has remained more or less at the same level.
Industry RankSector Rank
OM 47.63%
PM (TTM) 41.94%
GM 87.92%
OM growth 3Y-2.34%
OM growth 5Y3.56%
PM growth 3Y3.74%
PM growth 5Y3.86%
GM growth 3Y-1.56%
GM growth 5Y-1.06%
UTHR Yearly Profit, Operating, Gross MarginsUTHR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), UTHR is creating value.
  • UTHR has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, UTHR has less shares outstanding
  • There is no outstanding debt for UTHR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
UTHR Yearly Shares OutstandingUTHR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
UTHR Yearly Total Debt VS Total AssetsUTHR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 19.65 indicates that UTHR is not in any danger for bankruptcy at the moment.
  • UTHR has a Altman-Z score of 19.65. This is amongst the best in the industry. UTHR outperforms 89.42% of its industry peers.
  • UTHR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 19.65
ROIC/WACC1.88
WACC8.56%
UTHR Yearly LT Debt VS Equity VS FCFUTHR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B

2.3 Liquidity

  • UTHR has a Current Ratio of 6.60. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
  • UTHR has a better Current ratio (6.60) than 66.15% of its industry peers.
  • A Quick Ratio of 6.28 indicates that UTHR has no problem at all paying its short term obligations.
  • UTHR has a Quick ratio of 6.28. This is in the better half of the industry: UTHR outperforms 64.42% of its industry peers.
Industry RankSector Rank
Current Ratio 6.6
Quick Ratio 6.28
UTHR Yearly Current Assets VS Current LiabilitesUTHR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • UTHR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.41%, which is quite good.
  • The Earnings Per Share has been growing by 19.23% on average over the past years. This is quite good.
  • The Revenue has grown by 10.61% in the past year. This is quite good.
  • The Revenue has been growing by 16.50% on average over the past years. This is quite good.
EPS 1Y (TTM)13.41%
EPS 3Y22.93%
EPS 5Y19.23%
EPS Q2Q%24.39%
Revenue 1Y (TTM)10.61%
Revenue growth 3Y18.02%
Revenue growth 5Y16.5%
Sales Q2Q%7.38%

3.2 Future

  • UTHR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.75% yearly.
  • The Revenue is expected to grow by 11.03% on average over the next years. This is quite good.
EPS Next Y5.63%
EPS Next 2Y6.81%
EPS Next 3Y10.57%
EPS Next 5Y9.75%
Revenue Next Year5.72%
Revenue Next 2Y8.19%
Revenue Next 3Y10.1%
Revenue Next 5Y11.03%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
UTHR Yearly Revenue VS EstimatesUTHR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
UTHR Yearly EPS VS EstimatesUTHR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30 40 50

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 18.20 indicates a rather expensive valuation of UTHR.
  • Compared to the rest of the industry, the Price/Earnings ratio of UTHR indicates a rather cheap valuation: UTHR is cheaper than 94.04% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of UTHR to the average of the S&P500 Index (27.07), we can say UTHR is valued slightly cheaper.
  • A Price/Forward Earnings ratio of 17.23 indicates a rather expensive valuation of UTHR.
  • Based on the Price/Forward Earnings ratio, UTHR is valued cheaply inside the industry as 94.42% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 28.05. UTHR is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 18.2
Fwd PE 17.23
UTHR Price Earnings VS Forward Price EarningsUTHR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • UTHR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. UTHR is cheaper than 96.54% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, UTHR is valued cheaply inside the industry as 95.77% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 21.13
EV/EBITDA 10.87
UTHR Per share dataUTHR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • UTHR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)3.24
PEG (5Y)0.95
EPS Next 2Y6.81%
EPS Next 3Y10.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • UTHR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UNITED THERAPEUTICS CORP

NASDAQ:UTHR (3/2/2026, 1:48:55 PM)

507.91

+4.01 (+0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)04-28
Inst Owners98.84%
Inst Owner Change1.23%
Ins Owners1.84%
Ins Owner Change-2.94%
Market Cap21.87B
Revenue(TTM)3.18B
Net Income(TTM)1.33B
Analysts80.95
Price Target546.8 (7.66%)
Short Float %4.1%
Short Ratio4.45
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.35%
Min EPS beat(2)-2.35%
Max EPS beat(2)5.05%
EPS beat(4)1
Avg EPS beat(4)-1.8%
Min EPS beat(4)-9.46%
Max EPS beat(4)5.05%
EPS beat(8)2
Avg EPS beat(8)-2.1%
EPS beat(12)6
Avg EPS beat(12)0.77%
EPS beat(16)8
Avg EPS beat(16)-0.29%
Revenue beat(2)0
Avg Revenue beat(2)-4.27%
Min Revenue beat(2)-4.72%
Max Revenue beat(2)-3.81%
Revenue beat(4)1
Avg Revenue beat(4)-1.12%
Min Revenue beat(4)-4.72%
Max Revenue beat(4)6.71%
Revenue beat(8)4
Avg Revenue beat(8)0.39%
Revenue beat(12)7
Avg Revenue beat(12)1.48%
Revenue beat(16)9
Avg Revenue beat(16)1.26%
PT rev (1m)1.31%
PT rev (3m)5.12%
EPS NQ rev (1m)4.57%
EPS NQ rev (3m)3.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.46%
Revenue NQ rev (1m)-0.42%
Revenue NQ rev (3m)-0.69%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.09%
Valuation
Industry RankSector Rank
PE 18.2
Fwd PE 17.23
P/S 6.87
P/FCF 21.13
P/OCF 14.01
P/B 3.08
P/tB 3.13
EV/EBITDA 10.87
EPS(TTM)27.9
EY5.49%
EPS(NY)29.47
Fwd EY5.8%
FCF(TTM)24.04
FCFY4.73%
OCF(TTM)36.26
OCFY7.14%
SpS73.91
BVpS164.8
TBVpS162.09
PEG (NY)3.24
PEG (5Y)0.95
Graham Number321.64
Profitability
Industry RankSector Rank
ROA 16.94%
ROE 18.81%
ROCE 20.71%
ROIC 16.1%
ROICexc 26.8%
ROICexgc 27.52%
OM 47.63%
PM (TTM) 41.94%
GM 87.92%
FCFM 32.53%
ROA(3y)15.64%
ROA(5y)13.63%
ROE(3y)17.94%
ROE(5y)16.2%
ROIC(3y)15.88%
ROIC(5y)14.43%
ROICexc(3y)29.26%
ROICexc(5y)26.59%
ROICexgc(3y)30.21%
ROICexgc(5y)27.3%
ROCE(3y)20.42%
ROCE(5y)18.56%
ROICexgc growth 3Y0.25%
ROICexgc growth 5Y6.53%
ROICexc growth 3Y-0.12%
ROICexc growth 5Y7.38%
OM growth 3Y-2.34%
OM growth 5Y3.56%
PM growth 3Y3.74%
PM growth 5Y3.86%
GM growth 3Y-1.56%
GM growth 5Y-1.06%
F-Score8
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 614.49%
Cap/Sales 16.53%
Interest Coverage 112.28
Cash Conversion 97.49%
Profit Quality 77.56%
Current Ratio 6.6
Quick Ratio 6.28
Altman-Z 19.65
F-Score8
WACC8.56%
ROIC/WACC1.88
Cap/Depr(3y)462.52%
Cap/Depr(5y)380.04%
Cap/Sales(3y)11.66%
Cap/Sales(5y)9.87%
Profit Quality(3y)81.3%
Profit Quality(5y)87.1%
High Growth Momentum
Growth
EPS 1Y (TTM)13.41%
EPS 3Y22.93%
EPS 5Y19.23%
EPS Q2Q%24.39%
EPS Next Y5.63%
EPS Next 2Y6.81%
EPS Next 3Y10.57%
EPS Next 5Y9.75%
Revenue 1Y (TTM)10.61%
Revenue growth 3Y18.02%
Revenue growth 5Y16.5%
Sales Q2Q%7.38%
Revenue Next Year5.72%
Revenue Next 2Y8.19%
Revenue Next 3Y10.1%
Revenue Next 5Y11.03%
EBIT growth 1Y4.68%
EBIT growth 3Y15.26%
EBIT growth 5Y20.65%
EBIT Next Year10.74%
EBIT Next 3Y-7.03%
EBIT Next 5Y-7.27%
FCF growth 1Y-4.2%
FCF growth 3Y15.97%
FCF growth 5Y8.25%
OCF growth 1Y17.64%
OCF growth 3Y24.84%
OCF growth 5Y15.62%

UNITED THERAPEUTICS CORP / UTHR FAQ

What is the fundamental rating for UTHR stock?

ChartMill assigns a fundamental rating of 7 / 10 to UTHR.


What is the valuation status of UNITED THERAPEUTICS CORP (UTHR) stock?

ChartMill assigns a valuation rating of 6 / 10 to UNITED THERAPEUTICS CORP (UTHR). This can be considered as Fairly Valued.


Can you provide the profitability details for UNITED THERAPEUTICS CORP?

UNITED THERAPEUTICS CORP (UTHR) has a profitability rating of 9 / 10.


What are the PE and PB ratios of UNITED THERAPEUTICS CORP (UTHR) stock?

The Price/Earnings (PE) ratio for UNITED THERAPEUTICS CORP (UTHR) is 18.2 and the Price/Book (PB) ratio is 3.08.


What is the expected EPS growth for UNITED THERAPEUTICS CORP (UTHR) stock?

The Earnings per Share (EPS) of UNITED THERAPEUTICS CORP (UTHR) is expected to grow by 5.63% in the next year.